, Go Eun Bae
, Dong-Hyun Kim
, In-Ock Seong
, Kwang-Sun Suh
Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea
© 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PubReader
ePub Link
Cite this Article
| Clinicopathologic findings | GEA (n = 10) | UEA (n = 12) |
|---|---|---|
| Age (yr) | ||
| Mean ± SD | 61.7 ± 11.9 | 45.3 ± 10.9 |
| Range | 48–80 | 31–68 |
| Type of surgical treatment | ||
| Radical hysterectomy | 7 (70.0) | 8 (66.7) |
| Total hysterectomy | 0 | 3 (25.0) |
| Trachelectomy | 1 (10.0) | 0 |
| Conization | 2 (20.0) | 1 (8.3) |
| FIGO stage | ||
| I | 1 (10.0) | 9 (75.0) |
| II | 4 (40.0) | 1 (8.3) |
| III | 3 (30.0) | 2 (16.7) |
| IV | 2 (20.0) | 0 |
| Human papillomavirus status | ||
| High-risk HPV | 0 | 12 (100) |
| Not detected | 10 (100) | 0 |
| p16 expression | ||
| Block positive | 1 (10.0) | 12 (100) |
| Patchy positive/negative | 9 (90.0) | 0 |
| p53 expression | ||
| Diffuse strong positive | 5 (50.0) | 0 |
| Complete loss (null) | 1 (10.0) | 0 |
| Patchy positive | 4 (40.0) | 12 (100) |
| Follow-up results | ||
| No evidence of disease | 2 (20.0) | 9 (75.0) |
| Alive with disease | 3 (30.0) | 0 (0.0) |
| Died of disease | 4 (40.0) | 0 (0.0) |
| Died of other disease | 0 | 1 |
| Not available | 1 (10.0) | 2 (16.7) |
| Case No. | Age (yr) | Preparation type | Cytologic diagnosis | Type of surgery | FIGO stage | HPV | p16 | p53 | MUC-6 | Adjuvant treatment | Follow-up (mo) | Outcome | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| CS | LBP | ||||||||||||
| 1 | 48 | + | + | AIS | Trachelectomy | IVA | − | − | + | + | CC | 20 | DOD |
| 2 | 80 | + | + | Adenocarcinoma | RH | IIB | − | − | Wild | − |
RT | 38 | DOD |
| 3 | 52 | + | + | AGC | RH | IIIC1 | − | − | Wild | + | CCRT | 48 | AWD |
| 4 | 58 | + | + | Adenocarcinoma | RH | IVA | − |
− | + | + | CC | 23 | DOD |
| 5 | 54 | + | + | Adenocarcinoma | RH | IIA1 | − | + | + | + | NA | FU loss | NA |
| 6 | 54 | NA | NA | NA | Conization | IIIC1 | − | − | Wild | + | CCRT | 17 | DOD |
| 7 | 78 | NA | + | Adenocarcinoma | Conization | IIA2 | − | − | + | − |
RT | 21 | NED |
| 8 | 63 | NA | + | AGC | RH | IB1 | − | − | Null | + | CCRT | 21 | NED |
| 9 | 76 | NA | + | AGC | RH | IIB | − | − | + | + | RT | 10 | AWD |
| 10 | 54 | NA | NA | NA | RH | IIIC1 | − | − | Wild | + | CCRT | 10 | AWD |
| Cytologic finding | GEA (n=8) | UEA (n=12) | p-value |
|---|---|---|---|
| Mucinous background | .058 | ||
| Absent | 2 (25.0) | 2 (16.7) | |
| Focal | 2 (25.0) | 9 (75.0) | |
| Extensive | 4 (50.0) | 1 (8.3) | |
| Architecture | |||
| Monolayered honeycomb-like sheet | .002 | ||
| Absent | 0 | 6 (50.0) | |
| Focal | 1 (12.5) | 5 (41.7) | |
| Extensive | 7 (87.5) | 1 (8.3) | |
| 3-dimensional clusters | .010 | ||
| Absent | 0 | 0 | |
| Focal | 5 (62.5) | 1 (8.3) | |
| Extensive | 3 (37.5) | 11 (91.7) | |
| Feathering | .189 | ||
| Absent | 3 (37.5) | 3 (25.0) | |
| Focal | 5 (62.5) | 5 (41.7) | |
| Extensive | 0 | 4 (33.3) | |
| Nuclei | |||
| Vesicular nuclei | .057 | ||
| Absent | 0 (0.0) | 1 (8.3) | |
| Focal | 0 (0.0) | 5 (41.7) | |
| Extensive | 8 (100.0) | 6 (50.0) | |
| Hyperchromasia | .082 | ||
| Absent | 2 (25.0) | 0 | |
| Focal | 6 (75.0) | 9 (75.0) | |
| Extensive | 0 (0.0) | 3 (25.0) | |
| Nuclear groove | .230 | ||
| Absent | 0 (0.0) | 3 (25.0) | |
| Focal | 6 (75.0) | 8 (66.7) | |
| Extensive | 2 (25.0) | 1 (8.3) | |
| Nucleoli | .146 | ||
| Absent | 0 (0.0) | 3 (25.0) | |
| Focal | 3 (37.5) | 6 (50.0) | |
| Extensive | 5 (62.5) | 3 (25.0) | |
| Intranuclear pseudoinclusion | .761 | ||
| Absent | 7 (87.5) | 11 (91.7) | |
| Focal | 1 (12.5) | 1 (8.3) | |
| Extensive | 0 | 0 | |
| Cytoplasm | |||
| Vacuolar/granular | .001 | ||
| Absent | 0 | 2 (16.7) | |
| Focal | 0 | 8 (66.7) | |
| Extensive | 8 (100) | 2 (16.7) | |
| Golden-brown mucin | .089 | ||
| Absent | 3 (37.5) | 10 (83.3) | |
| Focal | 4 (50.0) | 2 (16.7) | |
| Extensive | 1 (12.5) | 0 | |
| Neutrophils | .461 | ||
| Absent | 0 | 1 (8.3) | |
| Focal | 2 (25.0) | 5 (41.7) | |
| Extensive | 6 (75.0) | 6 (50.0) | |
| Kawakami et al. [ |
Lu et al. [ |
Schwock et al. [ |
Ryu et al. [ |
This study | Total, n (%) | |
|---|---|---|---|---|---|---|
| No. of cases | 14 | 11 | 15 | 8 | 8 | 56 (100) |
| Preparation type | CS | LBC | CS and LBC | CS and LBC | CS and/or LBC | CS and/or LBC |
| TBS classification | ||||||
| Unsatisfactory | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
| NILM | 0 | 5 | 5 | 0 | 0 | 10 (17.9) |
| AGC | 3 | 4 | 2 | 4 | 3 | 16 (28.6) |
| AIS | 0 | 0 | 1 | 1 | 1 | 3 (5.4) |
| HSIL | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
| Adenocarcinoma | 11 | 0 | 7 | 3 | 4 | 25 (44.6) |
Values are presented as number (%) unless otherwise indicated. GEA, gastric-type endocervical adenocarcinoma; UEA, usual-type endocervical adenocarcinoma; SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus. Died of stomach cancer.
CS, conventional smear; LBP, liquid-based preparation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; AIS, adenocarcinoma in situ; CC, combined chemotherapy; DOD, died of disease; RH, radical hysterectomy; RT, radiotherapy; AGC, atypical glandular cells, favor neoplastic; CCRT, combined chemotherapy and radiotherapy; AWD, alive with disease; NA, not available; FU, follow-up; NED, no evidence of disease. Pale pinkish-red cytoplasmic neutral mucin on Alcian blue/PAS special staining; High risk HPV DNA in situ hybridization; +, p16, block-type positivity; +, p53, overexpression.
GEA, gastric-type endocervical adenocarcinoma; CS, conventional smear; LBC, liquid-based cytology; TBS, The Bethesda System; NILM, negative for intraepithelial lesion or malignancy; AGC, atypical glandular cells, not otherwise specified and favor adenocarcinoma; AIS, adenocarcinoma in situ; HSIL, high-grade squamous intraepithelial lesion.